Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Metronomic Chemo + Aspirin in Metastatic CRC
NCT04534218Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by CHU de Besançon. Started Oct 2020; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04534218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534218.